Biological Treatments for Pediatric Psoriasis: State of the Art and Future Perspectives

Int J Mol Sci. 2022 Sep 22;23(19):11128. doi: 10.3390/ijms231911128.

Abstract

Psoriasis is a chronic systemic inflammatory disease that primarily affects the skin and is associated with multiple comorbidities with a considerable reduction in quality of life of affected patients. One-third of psoriasis cases begin in childhood and are associated with significant medical comorbidities such as obesity, metabolic syndrome, arthritis, and psychiatric disorders. In addition, because of its chronic nature and frequent relapses, psoriasis tends to require long-term treatment. Treatment of pediatric psoriasis usually involves the same methods used for adults. However, most treatments for pediatric psoriasis are used off-label, and research in this regard is still lacking. Targeted therapies involving the use of newly developed biologic drugs are also increasingly being applied to childhood psoriasis. This review summarizes the clinical features of pediatric psoriasis and focuses mainly on the updated concepts of pathogenesis and biological treatments of pediatric psoriasis.

Keywords: biological treatments; biologics; pediatric psoriasis; psoriasis.

Publication types

  • Review

MeSH terms

  • Adult
  • Biological Products* / therapeutic use
  • Child
  • Chronic Disease
  • Comorbidity
  • Humans
  • Psoriasis* / drug therapy
  • Psoriasis* / epidemiology
  • Quality of Life
  • Skin / pathology

Substances

  • Biological Products

Grants and funding

This research received no external funding.